Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Wednesday, October 8, 2008

Pubmed paper: FMO (flavin-containing monooxygenase enzyme) induced in mice by aryl hydrocarbon.

Pubmed paper September 2008

This is a paper published recently by researchers at the University of Toronto, where mice were shown to have FMO3 induced by a xenobiotic (aryl hydrocarbon). It's unclear if this has any significance to poor FMO3 function in humans, but does seem to put a few small dents in what students are taught at medical school, that FMO3 enzyme is neither inducible nor inhibitable (although this was already disproven when indoles were shown to inhibit the enzyme in 1999). They were testing the detox enzymes with aryl hydrocarbon in 2006 and discovered FMO was inducible, so it looks like they concentrated on FMO in particular this time.

Probably most/all FMO/TMAU experts will regard FMO as uninducible.

The lead researcher was asked about the finding in an email, and replied that he doesn't think it has any promise to helping TMAU currently. He is about to retire and his lab does not research metabolism directly, so it looks like that line of research from that group may have run it's course. How much impact this has on understanding FMO is unkown.

The full paper is available free in PDF format on this site: Drug Metabolism and Disposition

It is not known whether TCDD can induce hepatic FMO3 in humans. We aligned the mouse AHR-associated region with human and rat genomes by a BLAT analysis (Kent, 2002); see Suppl Fig. 5). The mouse AHR-associated region showed minimal overlap with genomic sequences in human (26 of 78 base-pairs aligning) or in rat (20 of 78 base-pairs aligning). Further, the aligned regions are on separate chromosomes from the FMO3 gene in each species. Taken together these results suggest that the AHR-binding-element is part of a mouse-specific regulatory module and, at present, it cannot be inferred from promoter analysis in silico whether human FMO3 is likely to be inducible by AHR agonists.


Post a Comment